Statistics for CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer
Total visits
| views | |
|---|---|
| CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer | 180 |
Total visits per month
| views | |
|---|---|
| July 2024 | 10 |
| August 2024 | 5 |
| September 2024 | 9 |
| October 2024 | 0 |
| November 2024 | 2 |
| December 2024 | 0 |
| January 2025 | 0 |
File Visits
| views | |
|---|---|
| journal.pone.0139237.pdf | 149 |
Top country views
| views | |
|---|---|
| United States | 93 |
| China | 15 |
| Germany | 11 |
| Sweden | 9 |
| Japan | 6 |
| Singapore | 4 |
| Australia | 3 |
| India | 3 |
| Russia | 3 |
| Argentina | 2 |
| Finland | 2 |
| Mexico | 2 |
| Vietnam | 2 |
| Bangladesh | 1 |
| Belgium | 1 |
| Egypt | 1 |
| Hong Kong SAR China | 1 |
| Ireland | 1 |
| Ukraine | 1 |
Top city views
| views | |
|---|---|
| Ashburn | 48 |
| Norman | 11 |
| Fairfield | 9 |
| San Mateo | 4 |
| Boardman | 3 |
| Mumbai | 3 |
| Zhengzhou | 3 |
| Castro Valley | 2 |
| Chicago | 2 |
| Dallas | 2 |
| Des Moines | 2 |
| Hangzhou | 2 |
| Hanoi | 2 |
| Nanjing | 2 |
| Shenzhen | 2 |
| Singapore | 2 |
| Baltimore | 1 |
| Dublin | 1 |
| Esloev | 1 |
| Langhorne | 1 |
| Las Vegas | 1 |
| Leuven | 1 |
| Los Angeles | 1 |
| Melbourne | 1 |
| Odesa | 1 |
| Old Bridge | 1 |
| Perth | 1 |
| Phoenix | 1 |
| The Bronx | 1 |
| Wuhu | 1 |